Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8945-8951

  Tang, Yu ^a   Wang, Wei ^a   Teng, Xiu Zhi ^b   Shi, Lin ^a  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^b Department of Surgery Center Hospital of Liaoning Electric Power   (China)

Author keywords

Nedaplatin; Negative epidermal growth factor receptor mutation; Non small cell lung adenocarcinoma; S 1; Standard second line chemotherapy

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NEDAPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; AGRANULOCYTOSIS; ALLERGY; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; KIDNEY INJURY; LEUKOPENIA; LIVER INJURY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TOXIC HEPATITIS; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG THERAPY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NAUSEA; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NAUSEA; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; TEGAFUR; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 84919873898     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2155-y     Document Type: Article

References (21)

1. Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer. 2005;50 Suppl 2:S3–8.
2. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of l M tega—fur-O.4 M5一ehloro-2.4-dihydroxypyridine一1 M potassium oxonate (S-1)against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602–6.
3. Rieeiardi S, Tomao S. deMarinis F. Pemetrexed as first line therapy for non squamous non-small cell lung cancer [J]. Biomed Pharmacother. 2013;67(8):763–9.
4. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial [J]. Clin Cancer Res. 2004;10(23):7860–4.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med. 2002;10(346):92–8.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer [J]. N Engl J Med. 2005;353:123–32.
7. Yumine K, Kawaham M. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer] [J]. Gan To Kagaku Ryoho. 2006;33:189.
8. Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, et al. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009;64:1181–5.
9. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo controlled multicenter study (1ressa Survival Evaluation in Lung Cancer) [J]. Lancet. 2005;366:1527–37.
10. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer gefitinib [J]. N Engl J Med. 2004;350:2129–39.
11. Adjei AA. Pharmacology and mechanism of action of pemetrexed [J]. Clin Lung Cancer. 2004;5:S51–5.
12. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) [J]. J Clin Oncol. 2009; 27:abstrCRA8000.
13. Koizumi T, Kubo K, Shinozaki S, Koyama S, Amari T, Hayano T, et al. Pharmacokinetic evaluation of (glycolato-O, O')diammine platinum(II) in lung lymph in sheep. Jpn J Cancer Res. 1993;84:468–73.
14. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010;28:5240–6.
15. Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, et al. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6:790–5.
16. Shiroyama T, Komuta K, Imamura F, Hirashima T, Kijima T, Tachibana I, et al. Phase II study of S-1 monotherapy in platinum-refractory advanced non-small cell lung cancer. Lung Cancer. 2011;74:85–8.
17. Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, et al. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;66:913–8.
18. Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, et al. A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncol Lett. 2011;2:465–70.
19. Seto T, Yamanaka T, Wasada I, Seki N, Okamoto H, Ogura T, et al. Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: thoracic oncology research group study 0502. Lung Cancer. 2010;69:213–7.
20. Ono A, Naito T, Murakami H, Takahashi T, Nakamura Y, Tsuya A, et al. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. Int J Clin Oncol. 2010;15:161–5.
21. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al. Pemerexed combined with oxaliplatin or carboplatin as first line treatment in advanced non-small cell lung cancer: a multicenter randomized phaseIItreat [J]. Clin Cancer Res. 2005;15:690–6.